title: FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
abstract: Blast crisis chronic myelogenous leukemia (CML-BC) and Philadelphia chromosome-positive (Ph1-positive) acute lymphocytic leukemia (ALL) are 2 fatal BCR/ABL-driven leukemias against which Abl kinase inhibitors fail to induce a long-term response. We recently reported that functional loss of protein phosphatase 2A (PP2A) activity is important for CML blastic transformation. We assessed the therapeutic potential of the PP2A activator FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol hydrochloride), an immunomodulator in Phase III trials for patients with multiple sclerosis or undergoing organ transplantation, in CML-BC and Ph1 ALL patient cells and in in vitro and in vivo models of these BCR/ABL+ leukemias. Our data indicate that FTY720 induces apoptosis and impairs clonogenicity of imatinib/dasatinib-sensitive and -resistant p210/p190(BCR/ABL) myeloid and lymphoid cell lines and CML-BC(CD34+) and Ph1 ALL(CD34+/CD19+) progenitors but not of normal CD34+ and CD34+/CD19+ bone marrow cells. Furthermore, pharmacologic doses of FTY720 remarkably suppress in vivo p210/p190(BCR/ABL)-driven [including p210/p190(BCR/ABL)(T315I)] leukemogenesis without exerting any toxicity. Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients.
authors: Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA.
authors: Paolo
authors: P
authors: Neviani
authors: Ramasamy
authors: R
authors: Santhanam
authors: Joshua J
authors: JJ
authors: Oaks
authors: Anna M
authors: AM
authors: Eiring
authors: Mario
authors: M
authors: Notari
authors: Bradley W
authors: BW
authors: Blaser
authors: Shujun
authors: S
authors: Liu
authors: Rossana
authors: R
authors: Trotta
authors: Natarajan
authors: N
authors: Muthusamy
authors: Carlo
authors: C
authors: Gambacorti-Passerini
authors: Brian J
authors: BJ
authors: Druker
authors: Jorge
authors: J
authors: Cortes
authors: Guido
authors: G
authors: Marcucci
authors: Ching-Shih
authors: CS
authors: Chen
authors: Nicole M
authors: NM
authors: Verrills
authors: Denis C
authors: DC
authors: Roy
authors: Michael A
authors: MA
authors: Caligiuri
authors: Clara D
authors: CD
authors: Bloomfield
authors: John C
authors: JC
authors: Byrd
authors: Danilo
authors: D
authors: Perrotti
mesh_terms: D000818:Animals; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D000068876:Fingolimod Hydrochloride; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D015394:Molecular Structure; D010749:Phosphoprotein Phosphatases / Q000378:metabolism; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D011409:Propylene Glycols / Q000737:chemistry / Q000627:therapeutic use*; D054648:Protein Phosphatase 2; D011743:Pyrimidines / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D013844:Thiazoles / Q000494:pharmacology; D013997:Time Factors; D014407:Tumor Cells, Cultured
chemical_list: D001549:Benzamides; D010879:Piperazines; D011409:Propylene Glycols; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D010749:Phosphoprotein Phosphatases; D054648:Protein Phosphatase 2; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine; D000069439:Dasatinib
references: Nat Genet. 2002 Jan;30(1):48-58
references: 11753385
references: Leuk Res. 2002 Mar;26(3):301-10
references: 11792420
references: Br J Pharmacol. 2004 Nov;143(5):581-9
references: 15466446
references: Nature. 1973 Jun 1;243(5405):290-3
references: 4126434
references: Science. 1990 Feb 16;247(4944):824-30
references: 2406902
references: Mol Cell Biol. 1991 Apr;11(4):1988-95
references: 1706474
references: Proc Natl Acad Sci U S A. 1991 May 1;88(9):3589-93
references: 1708885
references: J Biol Chem. 1991 Aug 5;266(22):14486-90
references: 1860857
references: Nature. 1991 Sep 12;353(6340):170-3
references: 1716348
references: Blood. 1992 Dec 15;80(12):2983-90
references: 1467514
references: J Biol Chem. 1993 Jul 25;268(21):15523-30
references: 8393446
references: Blood. 1993 Sep 15;82(6):1929-36
references: 8400243
references: Leukemia. 1994 Jan;8(1):186-9
references: 8289486
references: Transplant Proc. 1998 Aug;30(5):2210-3
references: 9723444
references: J Exp Med. 1999 May 3;189(9):1399-412
references: 10224280
references: J Biol Chem. 1999 Sep 24;274(39):27351-8
references: 10488065
references: Carcinogenesis. 2004 Dec;25(12):2397-405
references: 15297371
references: Yonsei Med J. 2004 Dec 31;45(6):991-7
references: 15627289
references: Clin Cancer Res. 2005 Jan 1;11(1):12-9
references: 15671523
references: J Biol Chem. 2005 Feb 18;280(7):6238-44
references: 15569672
references: N Engl J Med. 2006 Jun 15;354(24):2542-51
references: 16775235
references: Blood. 2006 Sep 1;108(5):1478-84
references: 16627756
references: Br J Haematol. 1997 Jan;96(1):111-6
references: 9012696
references: Cancer Res. 2002 Mar 1;62(5):1410-9
references: 11888913
references: J Am Soc Nephrol. 2002 Apr;13(4):1073-83
references: 11912269
references: J Biol Chem. 2002 Jun 14;277(24):21453-7
references: 11967257
references: Blood. 2002 Sep 15;100(6):1965-71
references: 12200353
references: J Clin Invest. 2003 Mar;111(5):659-69
references: 12618520
references: Br J Pharmacol. 2003 Apr;138(7):1303-12
references: 12711631
references: Biochim Biophys Acta. 2003 May 12;1640(2-3):97-104
references: 12729918
references: Blood. 2003 May 15;101(10):4122-30
references: 12531792
references: Blood. 1994 Apr 15;83(8):2038-44
references: 8161775
references: Leuk Res. 1995 Jun;19(6):389-96
references: 7596151
references: Blood. 1995 Dec 15;86(12):4603-11
references: 8541551
references: Nat Med. 1996 May;2(5):561-6
references: 8616716
references: J Biol Chem. 1996 May 10;271(19):11059-62
references: 8626647
references: Blood. 1996 Oct 1;88(7):2375-84
references: 8839828
references: Oncogene. 1997 Nov 6;15(19):2333-42
references: 9393877
references: J Urol. 2003 Jun;169(6):2372-7
references: 12771800
references: Leuk Res. 2003 Aug;27(8):709-17
references: 12801529
references: Cancer. 2003 Oct 1;98(7):1337-54
references: 14508819
references: Cancer Res. 2003 Sep 15;63(18):5962-9
references: 14522923
references: Oncogene. 2003 Oct 20;22(47):7389-95
references: 14576846
references: Transplant Proc. 2004 Mar;36(2 Suppl):531S-543S
references: 15041402
references: J Clin Pharmacol. 2004 May;44(5):532-7
references: 15102874
references: J Org Chem. 2004 May 28;69(11):3950-2
references: 15153030
references: Blood. 2004 Jun 1;103(11):4010-22
references: 14982876
references: Prostaglandins Other Lipid Mediat. 2004 Jan;73(1-2):29-45
references: 15165029
references: Am J Transplant. 2004 Jul;4(7):1019-25
references: 15196057
references: Hematol Oncol Clin North Am. 2004 Jun;18(3):545-68, vii-viii
references: 15271392
references: Nat Rev Cancer. 2004 Aug;4(8):604-16
references: 15286740
references: Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14788-93
references: 15466700
references: IDrugs. 2005 Mar;8(3):236-53
references: 15772896
references: Blood. 2005 Apr 1;105(7):2640-53
references: 15618470
references: Circ Res. 2005 Apr 29;96(8):913-20
references: 15802614
references: Cancer Res. 2005 Jun 1;65(11):4500-5
references: 15930265
references: Nat Med. 2005 Jun;11(6):630-7
references: 15908956
references: Clin Sci (Lond). 2005 Jul;109(1):13-25
references: 15966868
references: Mol Cell Biol. 2005 Aug;25(15):6464-74
references: 16024784
references: Cancer Res. 2005 Aug 15;65(16):7478-84
references: 16103102
references: J Immunol. 2005 Sep 1;175(5):2913-24
references: 16116177
references: Mol Cancer Ther. 2005 Sep;4(9):1430-8
references: 16170036
references: J Clin Pharmacol. 2005 Nov;45(11):1268-78
references: 16239360
references: Cancer Cell. 2005 Nov;8(5):355-68
references: 16286244
references: Pharmacol Ther. 2005 Dec;108(3):308-19
references: 15951022
references: Clin Cancer Res. 2005 Dec 1;11(23):8458-66
references: 16322309
references: Blood. 2006 Feb 15;107(4):1454-8
references: 16223773
references: NeuroRx. 2005 Oct;2(4):638-49
references: 16489371
references: Blood. 2006 Mar 15;107(6):2507-16
references: 16293596
references: N Engl J Med. 2006 Jun 15;354(24):2531-41
references: 16775234
references: Blood. 2000 Feb 1;95(3):1007-13
references: 10648416
references: Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10832-7
references: 10995457
references: Biochem Biophys Res Commun. 2001 Feb 23;281(2):282-8
references: 11181042
references: Biochem J. 2001 Feb 1;353(Pt 3):417-39
references: 11171037
references: Cell Signal. 2001 Jan;13(1):7-16
references: 11257442
references: N Engl J Med. 2001 Apr 5;344(14):1038-42
references: 11287973
references: J Interferon Cytokine Res. 2001 Jun;21(6):369-78
references: 11440634